Immune Checkpoint Inhibitor Market
Immune Checkpoint Inhibitor Market Study by PD-1, PD-L1 and and CTLA-4 Drug Class for Lung Cancer, Melanoma, Squamous Cell Carcinoma, Urothelial Carcinoma, and Lymphoma from 2024 to 2034
Analysis of Immune Checkpoint Inhibitor Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Immune Checkpoint Inhibitor Market Outlook
The global immune checkpoint inhibitor market size is projected to reach US$ 26,826.0 million in 2024. The sales of immune checkpoint inhibitors are expected to witness a strong CAGR of 14.7% from 2024 to 2034. By 2034, the immune checkpoint inhibitor demand is anticipated to reach a valuation of US$ 1,06,155.7 million.
Dynamic Elements Fostering Advancements in the Immune Checkpoint Inhibitor
The increasing global prevalence of various forms of cancer significantly compels the immune checkpoint inhibitor (ICIs) market. The demand for immune checkpoint inhibitors (ICIs) is expected to increase as ICIs demonstrate promise in treating multiple cancer types.
The immune checkpoint inhibitors (ICIs) market is driven by ongoing studies and advancements in cancer immunotherapy, particularly ICIs. The immune checkpoint inhibitor (ICIs) industry is growing due to ongoing efforts to improve knowledge of the immune system's role in cancer and the creation of innovative immunotherapeutic strategies.
The immune checkpoint inhibitor (ICIs) market expansion is facilitated by advancements in emerging markets' healthcare infrastructure and the availability of cutting-edge cancer treatments. Immune checkpoint inhibitor adoption is projected to rise as healthcare systems develop and become more sophisticated.
Regulatory approvals of immune checkpoint inhibitors facilitate market expansion for broader use in various cancer types and novel indications. The market opportunity for ICIs rises with the expansion of approved indications.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 26,826.0 million |
| Forecasted Market Value (2034F) | US$ 1,06,155.7 million |
| Global Market Growth Rate (2024 to 2034) | 14.7% |
| PD-1 Segment Growth Rate (2024 to 2034) | 14.8% |
| Lung Cancer Segment Growth Rate (2024 to 2034) | 15.0% |
| Retail Pharmacies Segment Growth Rate (2024 to 2034) | 14.9% |
| North America Market Share (2024) | 13.8% |
| Latin America Market Share (2024) | 17.7% |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Deterrents in the Immune Checkpoint Inhibitor Market
A significant limitation can be immune checkpoint inhibitor safety concerns and side effects. Immune checkpoint inhibitor resistance can develop over time, and some individuals do not respond to it. The impact of these therapies is limited by the development of resistance or lack of response, which restricts sales of immune checkpoint inhibitors.
Immune checkpoint inhibitors are extremely expensive, burdening people and healthcare systems financially. A significant percentage of the population cannot obtain it due to the expensive cost, which impedes immune checkpoint inhibitor market expansion.
Strict regulatory criteria and approval procedures partly cause delays in releasing novel immune checkpoint inhibitors on the market. The immune checkpoint inhibitor (ICIs) market expansion is hampered by the delayed availability of novel medicines due to the sluggish rate of regulatory approvals.
Country-wise Analysis
The immune checkpoint inhibitor market in North America is anticipated to develop at a CAGR of 13.8% through 2034. Rising demand for immune checkpoint inhibitors in leading countries, especially the United States and Canada, is the primary catalyst behind the spike. The United States tops the immune checkpoint inhibitor industry with an estimated share of 96.2% by 2034.
The immune checkpoint inhibitor (ICIs) market in Latin America is anticipated to advance at a 17.7% CAGR through 2034. Brazil has emerged as the dominant force, with a 90.9% share in the immune checkpoint inhibitor market by 2034.
What Are the Prospects for Immune Checkpoint Inhibitors in North America?
“Biomarker Research Is Crucial for Optimizing Immune Checkpoint Inhibitor Effectiveness”
Immune checkpoint inhibitors enter the market quickly because of the FDA's expedited approval procedures, giving patients prompt access to innovative therapies. The United States is a critical market for immune checkpoint inhibitors due to the rising incidence of different tumors and an aggressive healthcare system. In 2024, the immune checkpoint inhibitor market in the United States is expected to capture a 96.0% share.
| Attribute | Details |
|---|---|
| United States Market CAGR | 13.8% |
| United States Market Size (2024) | US$ 16,663 million |
| Canada Market CAGR | 13.3% |
| Canada Market Size (2024) | US$ 676 million |
The increased focus impacts Canada's immune checkpoint inhibitor market on precision medicine, resulting in tailored and focused treatment strategies. Immune checkpoint inhibitors are widely accessible to patients in Canada due to the healthcare system's emphasis on inclusion, which also promotes equity in cancer treatment options. In 2024, Canada's immune checkpoint inhibitor (ICIs) market is expected to acquire a share of 3.9%.
How Promising Is the Latin America Immune Checkpoint Inhibitor Market?
“Regulatory Approvals for Novel Immunotherapeutic Agents Contribute to the Dynamic Market Landscape”
Immunotherapy-responsive malignancies are becoming more common, and this, together with Brazil's dedication to cancer research, is driving the market uptake of immune checkpoint inhibitors. To promote greater patient accessibility, immunological checkpoint inhibitor pricing and reimbursement strategies must consider socioeconomic aspects impacting Brazil's healthcare access. In 2024, the Brazil immune checkpoint inhibitor market is predicted to possess a 90.2% share.
| Attribute | Details |
|---|---|
| Brazil Market CAGR | 17.8% |
| Brazil Market Size (2024) | US$ 393 million |
| Chile Market CAGR | 17.2% |
| Chile Market Size (2024) | US$ 15 million |
Immune checkpoint inhibitors can have a significant influence on the nation's cancer treatment options owing to Chile's dedication to reducing health inequities and improving oncology care. The growth of the Chilean healthcare system and its focus on precision medicine highlight the increasing interest in immune checkpoint inhibitors, which is consistent with global trends in tailored cancer medicines. In 2024, the Chile market is expected to get a 3.4% share.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Outlook
Based on the drug class, the PD-1 segment is estimated to hold an 86.0% market share by 2034. Simultaneously, the CTLA-4 segment is anticipated to secure a noteworthy 9.7% share by 2034, contributing significantly to the market's resource diversity. Based on application, the lung cancer segment marks its dominance, with a share of 31.2% by 2034.
How Does the PD-1 Segment Surpass Other Drug Classes in the Immune Checkpoint Inhibitor Market?
“PD-1 Inhibitors Exhibit Higher Therapeutic Efficacy in Various Cancers”
| PD-1 | Details |
|---|---|
| Market Size (2024) | US$ 22,882.0 million |
| Market Share (2024) | 85.3% |
| CTLA-4 | Details |
|---|---|
| Market Size (2024) | US$ 2,739.6 million |
| Market Share (2024) | 10.2% |
PD-1 inhibitors demonstrate higher clinical efficacy and broader applicability across various cancer types. Uniform expression across different tumor types presents an obstacle for PD-L1 inhibitors.
CTLA-4 inhibitors are effective but can only be used for certain types of cancer. In contrast to CTLA-4 inhibitors, PD-1 inhibitors have a more favorable safety profile.
Its market domination is fueled by ongoing research highlighting PD-1 as a critical target. The segment growth of PD-1 inhibitors can be boosted by their potential for use in combination therapies.
Does Lung Cancer Take the Lead in the Immune Checkpoint Inhibitor Market by Application?
“Paradigm Shift Toward Immunotherapy in Lung Cancer Enhances Inhibitor Market Dominance.”
| Lung Cancer | Details |
|---|---|
| Market Size (2024) | US$ 8,208.0 million |
| Market Share (2024) | 30.6% |
| Melanoma | Details |
|---|---|
| Market Size (2024) | US$ 6,386.0 million |
| Market Share (2024) | 23.8% |
Worldwide lung cancer incidence is high, which drives up demand for immune checkpoint inhibitors. Immunotherapy has become dominant in lung cancer treatment, with immune checkpoint inhibitors at the forefront of this paradigm change. The application category's lung cancer section is expected to evolve at a 15.0% CAGR from 2024 to 2034. Sustaining market leadership is facilitated by ongoing investigations into and advancements in the adoption of immune checkpoint inhibitors in many subtypes of lung cancer.
Competitive Analysis
The immune checkpoint inhibitor market is characterized by moderate rivalry, with significant competitors employing tactical moves to strengthen their position in the market. Significant immune checkpoint inhibitor vendors seek to expand through mergers, acquisitions, and joint research projects to strengthen their position in the market.
A significant amount of funding is going into clinical trials to increase the range of indications currently prescribed medications can address. By taking a proactive approach, this strategy aims to expand market share by tackling the unaddressed issues brought forth by the disease load. The immune checkpoint inhibitor (ICIs) market is characterized by dynamic dynamics demonstrating dedication to innovation and thorough responsiveness to the changing needs of patients and healthcare stakeholders.
Noteworthy Advancements
- As a first-line treatment for patients with unresectable advanced, recurring, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression of 1%, Bristol Myers Squibb was granted clearance by the European Commission in April 2022 for opdivo (nivolumab) combined with chemotherapy.
- In March 2022, Merck announced that the FDA had approved its anti-PD-1 therapy, KEYTRUDA, as a stand-alone medication for the treatment of patients with advanced endometrial carcinoma who are either mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H), as determined by an approved test; these patients have disease progression after previous systemic therapy in any setting and are not candidates for radiation or curative surgery.
- The immune checkpoint inhibitor tislelizumab received clearance from the European Medicines Agency (EMA) in April 2022, as disclosed by Novartis. Its use in individuals with locally advanced or metastatic non-small cell lung cancer (NSCLC), whether squamous or non-squamous, is approved as a first-line treatment in conjunction with chemotherapy. The approval also covers the use of tislelizumab as monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) and unresectable, recurrent, locally progressed, or metastatic esophageal carcinoma following previous treatment.
- Acquiring Trillium Therapeutics, based in Cambridge, Massachusetts, and Toronto, for US$ 2.26 billion was announced by Pfizer in August of 2021. Trillium is developing a novel family of checkpoint inhibitors to treat cancer.
- Merck & Co. Inc. completed the acquisition of ArQule, Inc. from Zedi in January 2020. The company's output of linked healthcare items increased due to this acquisition.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Segmentation of Immune Checkpoint Inhibitor (ICIs) Market Research
-
By Drug Class:
- PD-1
- PD-L1
- CTLA-4
-
By Application:
- Lung Cancer
- Melanoma
- Squamous Cell Carcinoma
- Urothelial Carcinoma
- Lymphoma
- Other Cancers
-
By End Users:
- Hospital Pharmacies
- Retail Pharmacies
-
By Region:
- North America
- Latin America
- East Asia
- South Asia and Pacific
- Western Europe
- Eastern Europe
- The Middle East and Africa
- FAQs -
What Was the Value of the Immune Checkpoint Inhibitor (ICIs) Market in 2019?
The global immune checkpoint inhibitor market was worth US$ 13,373.7 million in 2019.
What Is the Sales Outlook for the Immune Checkpoint Inhibitor (ICIs) Market in 2024?
The sales of immune checkpoint inhibitors are likely to be valued at US$ 26,826.0 million in 2024.
What Is the Demand Forecast for Immune Checkpoint Inhibitor Market?
Demand for immune checkpoint inhibitors is projected to reach a market value of US$ 1,06,155.7 million by 2034.
What Is the Adoption Growth Projection for the Immune Checkpoint Inhibitor (ICIs) Market?
Adoption of immune checkpoint inhibitors is projected to rise at a CAGR of 14.7% through 2034.
At What CAGR Is the Immune Checkpoint Inhibitor (ICIs) Market in North America Predicted to Grow?
The North America immune checkpoint inhibitor market is forecast to expand at a CAGR of 13.8% through 2034.
At What CAGR Is the Immune Checkpoint Inhibitor (ICIs) Market in Latin America Predicted to Grow?
The Latin America immune checkpoint inhibitor market is forecast to expand at a CAGR of 17.7% through 2034.
Immune Checkpoint Inhibitor Market
*Mail attachment includes 120 figures & 24 tables